Riligustilide alleviates hepatic insulin resistance and gluconeogenesis in T2DM mice through multitarget actions

Phytother Res. 2022 Jan;36(1):462-474. doi: 10.1002/ptr.7346. Epub 2021 Dec 13.

Abstract

Riligustilide (RG), one of the dimeric phthalides of Angelica sinensis and Ligusticum chuanxiong, was confirmed effective against many diseases. However, its effects on type 2 diabetes mellitus (T2DM) and the underlying molecular mechanisms have not been clearly elucidated yet. The current study was designed to investigate the hypoglycemic potential by which RG affects the pathogenesis of T2DM. Comprehensive insights into the effects and underlying molecular mechanisms of RG on attenuating aberrant metabolism of glucose were determined in high-fat diet-induced T2DM mice and insulin-resistant (IR) HepG2 cells. In high-fat diet-induced C57BL/6J mice, RG administration significantly reduced hyperglycemia, decreased hyperinsulinemia, and ameliorated glucose intolerance. Mechanistically, RG activated PPARγ and insulin signaling pathway to improve insulin sensitivity, and increase glucose uptake as well as glycogenesis. In addition, RG also upregulated AMPK-TORC2-FoxO1 axis to attenuate gluconeogenesis in vivo and in vitro. According to the findings, RG may be a promising candidate for the treatment of T2DM.

Keywords: T2DM; gluconeogenesis; glycogenesis; insulin resistant; riligustilide.

MeSH terms

  • Animals
  • Benzofurans
  • Diabetes Mellitus, Type 2* / drug therapy
  • Gluconeogenesis
  • Insulin Resistance*
  • Mice
  • Mice, Inbred C57BL

Substances

  • Benzofurans
  • riligustilide